

# Ferinject Patient Enrolment & Medical Order Form

## Patient Information

|  |             |   |  |   |                  |   |  |
|--|-------------|---|--|---|------------------|---|--|
| Last Name*   |             | First Name*   |  | Date of Birth* (dd/mmm/yy)  | Health Card No.* | Gender*<br><input type="checkbox"/> M <input type="checkbox"/> F  |  |
| Street Number  | Street Name |   |  | City/Town   | Province         | Postal Code   |  |
| Phone (Home)*<br><input type="checkbox"/> Y <input type="checkbox"/> N Consent to leave message  |             | Phone (Work)*<br><input type="checkbox"/> Y <input type="checkbox"/> N Consent to leave message |  | Phone (Cell)*<br><input type="checkbox"/> Y <input type="checkbox"/> N Consent to leave message   |                  | Email*  |  |
| Diagnosis  |             |   |  | Allergies   |                  | Patient on Beta-blocker / ACE inhibitor?<br><input type="checkbox"/> Y <input type="checkbox"/> N Specify |  |
| CVAD (please submit protocol directive)<br><input type="checkbox"/> Portacath <input type="checkbox"/> PICC <input type="checkbox"/> N/A |             | Mobility Device   |  | <input type="checkbox"/> Wheelchair <input type="checkbox"/> Walker <input type="checkbox"/> None |                  |   |  |

## Physician Information

|                      |              |                       |  |                  |           |   |  |
|----------------------|--------------|-----------------------|--|------------------|-----------|---|--|
| Physician Last Name* |              | Physician First Name* |  | Designation*     | License*  |   |  |
| Street Number*       | Street Name* |                       |  | City/Town*       | Province* | Postal Code*  |  |
| Physician Office*    |              | Physician Fax*        |  | Physician Email* |           | Preferred method of communication*<br><input type="checkbox"/> Phone <input type="checkbox"/> Email |  |
| Nurse Last Name      |              | Nurse First Name      |  | Nurse Phone      |           |   |  |

## Medical Order\*

|  |  |  |  |                           |                    |
|--|--|--|--|---------------------------|--------------------|
| <b>Ferinject (ferric carboxymaltose) IV in Adults</b>  |  |  |  | Provincial Approval Code* | Body Weight*<br>Kg |
| <small>Note: Single Ferinject infusion in adults should not exceed 15mg iron/kg body weight or 1000mg of iron. If the total iron need is higher than 1000mg, then the administration of the additional dose should be a minimum of 7 days apart from the first dose.</small> |  |  |  |                           |                    |

| Hb (g/dL) | BW below 35 kg                                 | BW 35 kg to under 70kg  |  | BW 70kg and above  |
|-----------|--|---|--|--|
| <10       | <input type="checkbox"/> 500mg single infusion | <input type="checkbox"/> 1500mg (as three 500mg weekly infusions for BW 35kg to under 67kg) | <input type="checkbox"/> 1500mg (as 1000mg and 500mg infusions 1 week apart for BW 67kg to under 70kg) | <input type="checkbox"/> 2000mg (as two 1000mg weekly infusions)             |
| 10 to <14 | <input type="checkbox"/> 500mg single infusion | <input type="checkbox"/> 1000mg (as two 500mg weekly infusions for BW 35kg to under 67kg)   | <input type="checkbox"/> 1000mg as single infusion for BW 67kg to under 70kg                           | <input type="checkbox"/> 1500mg (as 1000mg and 500mg infusions 1 week apart) |
| ≥14       | <input type="checkbox"/> 500mg single infusion | <input type="checkbox"/> 500mg single infusion  |  | <input type="checkbox"/> 500mg single infusion                               |

|  |  |  |  |                           |                    |
|--|--|--|--|---------------------------|--------------------|
| <b>Ferinject (ferric carboxymaltose) IV in Pediatric Patients aged 12 to 17 years</b>  |  |  |  | Provincial Approval Code* | Body Weight*<br>Kg |
| <small>Note: Single Ferinject infusion in pediatric patients should not exceed 15mg iron/kg body weight or 750 mg of iron. If the total iron need is higher than 750 mg, then the administration of the additional dose should be a minimum of 7 days apart from the first dose.</small> |  |  |  |                           |                    |

| Hb (g/dL) | 30 kg  | 40 kg   | 50 kg   | 60 kg   |
|-----------|--|---|---|---|
| 7         | <input type="checkbox"/> 900mg (as two 450mg weekly infusions)             | <input type="checkbox"/> 1200mg (as two 600mg weekly infusions)             | <input type="checkbox"/> 1350mg (as 750mg and 600mg infusions 1 week apart) | <input type="checkbox"/> 1500mg (as two 750mg weekly infusions)             |
| 9         | <input type="checkbox"/> 750mg (as 400mg and 350mg infusions 1 week apart) | <input type="checkbox"/> 1100mg (as 600mg and 500mg infusions 1 week apart) | <input type="checkbox"/> 1200mg (as two 600mg weekly infusions)             | <input type="checkbox"/> 1350mg (as 750mg and 600mg infusions 1 week apart) |
| 11        | <input type="checkbox"/> 600mg (as 300mg and 300mg infusions 1 week apart) | <input type="checkbox"/> 900mg (as 500mg and 400mg infusions 1 week apart)  | <input type="checkbox"/> 1000mg (as two 500mg weekly infusions)             | <input type="checkbox"/> 1100mg (as 600mg and 500mg infusions 1 week apart) |
| <13       | <input type="checkbox"/> 450mg single infusion                             | <input type="checkbox"/> 700mg (as 400mg and 300mg infusions 1 week apart)  | <input type="checkbox"/> 750mg as single infusion                           | <input type="checkbox"/> 800mg (as two 400mg weekly infusions)              |
| ≥15       | <input type="checkbox"/> 450mg single infusion                             | <input type="checkbox"/> 500mg single infusion                              | <input type="checkbox"/> 500mg single infusion                              | <input type="checkbox"/> 500mg single infusion                              |

Other instructions:

PRE-Medications

PRN/PRE Medications

- |  |   |
|--|---|
| <input type="checkbox"/> Acetaminophen 325-650 mg PO PRN q 4-6 hours for pain, fever or chills<br><input type="checkbox"/> Diphenhydramine 25-50 mg PO/IV PRN q 4-6 hours for itching, urticaria, pruritis, hives<br><input type="checkbox"/> Dimenhydrinate 25-50 mg PO/IV PRN q 4-6 hours for nausea and vomiting<br><input type="checkbox"/> Hydrocortisone 100 mg IV PRN x 1 for anaphylactic reaction<br><input type="checkbox"/> Epinephrine (1:1000) 0.01 mL/kg (max 0.5 mL) SC/IM PRN q 10-15 minutes x 2 for severe anaphylactic reaction | <input type="checkbox"/> Oxygen via mask/nasal prongs 2-5 L/min PRN for SOB or decreasing O2 sat (below 90% if lower than baseline)<br><input type="checkbox"/> Salbutamol 2 puffs q 4-6 hours via aerochamber PRN for dyspnea or wheezing<br><input type="checkbox"/> Salbutamol 2.5 mg nebule for inhalation by nebulizer PRN for dyspnea or wheezing x 1 dose<br><input type="checkbox"/> Other: |
|--|---|

**Special Instructions**

- |  |                   |
|--|-------------------|
| <input type="checkbox"/> If there is a variance in the patient's weight of more than (select one) %<br><input type="checkbox"/> I would like a copy of the post-infusion reports <input type="checkbox"/> Physician Fax <input type="checkbox"/> the following number: | Please contact me |
|--|-------------------|

**Authorization\***

- I have reviewed the warnings and precautions for this medication including the risk of infusion associated reactions and the risks of paravenous leakage which can cause irritation of the skin and potential for long-lasting brown discoloration at the injection site with the patient above and/or their substitute decision maker.

Physician Signature\*

Date\* (dd/mmm/yy)

**Patient Consent\***

The Bayshore Direct Care™ Program (the "Program") is provided by Bayshore Specialty Rx Ltd. ("Bayshore"). The Program offers certain patient support services which may include, as applicable, nursing services, injection and infusion of medication services, insurance reimbursement assistance and pharmacy services ("Services"). Bayshore reserves the right to modify or terminate the Program at any time without prior notice.

Bayshore is committed to protecting patient confidentiality and patient health information, including without limitation personal information (name, address, contact details, date of birth, financial information) and health information (medical history and conditions, health insurance) (collectively, "Personal Health Information") in accordance with all applicable laws.

My healthcare provider has prescribed certain medication as identified above ("Product/s") for my use and has referred me to the Program. I have discussed the benefits and risks of use of the Product/s with my healthcare provider, I am not relying on the Program for the provision of any medical advice or diagnoses, and I have decided to start treatment on the Product/s. I would like to enrol in the Program to receive Services in relation to Product/s. By signing below, I acknowledge, understand and agree as follows:

- The Program shall collect, use, disclose and/or store (collectively, "Use") my Personal Health Information for the purpose of providing the Services, monitoring the Program, reporting adverse events or as may be required by applicable law. My Personal Health Information may be collected from and/or disclosed to my physicians, nurses, pharmacists, insurance providers and others as may be required to provide the Services;
- The Program may contact me by telephone or electronic mail using the contact information I have provided above, and I shall be responsible for any resulting telecommunication charges;
- My physician may provide this completed, signed Bayshore Direct Care Patient Enrolment & Medical Order form to the Program;
- My insurance provider may disclose to the Program my insurance coverage information, and I consent to the Use by the Program of such information for the purpose of verifying coverage and otherwise arranging for reimbursement for the Product/s.
- The Program shall be my designated agent for purposes of assisting and selecting the pharmacy that will supply the Product and for purposes of forwarding the prescription, by fax or other mode of delivery, to the pharmacy chosen. This prescription represents the original of the prescription drug order and the receiving pharmacy is the only intended recipient and there are no others. The original prescription has been invalidated and securely filed, and it will not be transmitted by the Program at another time.
- My participation in this Program is voluntary, and I may withdraw this consent at any time by calling the Program at 1-877-261-4940 or by mail to Bayshore HealthCare Ltd., Direct Care Program at 2101 Hadwen Road, Mississauga, ON L5K 2L3. I further understand that withdrawal of my consent will end the Use of my Personal Health Information by the Program and will result in termination of my participation in the Program and use of the Services. I may request access to or correction of my Personal Health Information by contacting the Program at 1-877-261-4940 or by mail to Bayshore HealthCare Ltd., Direct Care Program at 2101 Hadwen Road, Mississauga, ON L5K 2L3.

Signature of Patient/Legal Representative\*

Printed Name of Patient/Legal Representative\*

Date\* (dd/mmm/yy)

Verbal Consent Obtained\*

Date\* (dd/mmm/yy)

- Yes